Pfizer is offering a fellowship program specifically for “early career colleagues of Black/African American, Latino/Hispanic and Native American descent.'
a "Breakthrough Fellowship Program," which includes a scholarship for a graduate degree and guaranteed employment, for students and "early career colleagues of Black/African American, Latino/Hispanic and Native American descent," a requirement that could run afoul of federal law.
The program, which aims to enroll 100 fellows within three years, is a 9-year commitment for those who are accepted. In addition to a fully-funded master's degree, fellows also get a summer internship, two years of employment after undergraduate graduation, and a return to Pfizer after graduate studies.
The pharmaceutical giant lists several requirements for potential applicants, such as demonstrating "exceptional leadership potential," having, and meeting the "program’s goals of increasing the pipeline for Black/African American, Latino/Hispanic and Native Americans." "One of Pfizer’s Bold Moves is to create a workplace for all, and we are committed to increasing diversity by fostering a more inclusive workplace," the company wrote. Asian Americans, a minority that makes up 6.1% of the US population, are not included in Pfizer's list of minorities who can apply. White Americans, who make up 59.3% of the population, also aren't included.
Gail Heriot, a University of San Diego law professor and member of the U.S. Commission on Civil Rights, told the Washington Free Beacon that the program has a "clear case of liability" under federal law, which prohibits employment discrimination based on race.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
FDA authorizes Pfizer and Moderna's updated Covid-19 boostersThe US Food and Drug Administration authorized updated Covid-19 vaccine booster shots from Moderna and Pfizer. This is the first time updated Covid-19 vaccines have received emergency use authorization in the United States.
Weiterlesen »
PolitiFact - Moderna’s lawsuits against Pfizer do not prove the COVID-19 vaccine existed before the pandemicScientists used mRNA technology to study other viruses before COVID-19. Moderna is suing Pfizer-BioNTech for infringing patents on mRNA technology filed between 2010 and 2016.
Weiterlesen »
U.S. clears updated Moderna, Pfizer boosters targeting newest variantsNEW: The U.S. on Wednesday authorized its first update to COVID-19 vaccines, booster doses that target today’s most common omicron strain. Shots could begin within days.
Weiterlesen »
Moderna patent fight about feathers, not gooseModerna’s claim that the Covid-19 vaccine developed by Pfizer and partner BioNTech used its intellectual property sounds explosive. The sums at stake are potentially huge, as the drug giant estimates sales of the vaccine will be $32 billion this year. It’s in nobody’s interest to kill this golden goose though. The most likely result will simply be lots of legal hissing, and at worst for Pfizer, a few plucked feathers.
Weiterlesen »
FDA Authorizes Updated COVID Boosters to Target Newest VariantsThe FDA has granted emergency use authorization to Omicron-specific COVID-19 vaccines made by Pfizer/BioNTech and Moderna.
Weiterlesen »
FDA authorizes first revamp of COVID vaccines to target omicronThe new shots from Moderna and Pfizer-BioNTech target both the original strain of the coronavirus and the omicron BA.4/BA.5 subvariants that most people are catching now.
Weiterlesen »